There is no single fixed duration for hormone replacement therapy (HRT). How long you take it depends on why you started, how you respond, and your individual health risks. The old advice to stop after five years is outdated. Current guidelines from major medical organizations recommend an individualized approach, with yearly check-ins to weigh the benefits against the risks.
The Five-Year Rule Is No Longer Standard
For years, many women were told to limit HRT to five years or less. That advice stemmed largely from a landmark study in the early 2000s that linked combined hormone therapy to increased breast cancer risk. But the medical understanding has evolved considerably since then. The North American Menopause Society now states that HRT “does not need to be routinely discontinued in women aged older than 60 or 65 years.” Instead, the decision to continue or stop should be based on your specific symptoms, your response to treatment, and your personal risk factors for conditions like heart disease, blood clots, and breast cancer.
The general principle is straightforward: use the lowest effective dose for as long as you need it. If your symptoms persist and significantly affect your quality of life, longer treatment is reasonable. If your symptoms have faded and your risks are climbing, it may be time to taper off.
When You Start Matters
The safety window for beginning HRT is one of the most important factors in how long you can comfortably stay on it. Starting before age 60, or within 10 years of your final period, is associated with a more favorable balance of benefits to risks. If you start after 60 or more than a decade past menopause, the risk of serious complications like stroke, blood clots, and heart disease increases.
This means a woman who begins HRT at 50 has a wider runway for continued use than someone who starts at 62. Your starting point essentially sets the terms for the conversation you’ll have with your doctor each year about whether to keep going.
Early Menopause Changes the Timeline
If you experienced menopause before age 40 (a condition called primary ovarian insufficiency) or had your ovaries surgically removed at a young age, the timeline looks very different. The American College of Obstetricians and Gynecologists recommends that women in this situation continue HRT until at least age 50 to 51, which is the average age of natural menopause. This isn’t optional in the way it might be for someone going through menopause at the typical age. Your body lost its hormone supply earlier than expected, and replacing those hormones until the point when they would have naturally declined protects your bones, heart, and overall health.
Estrogen-Only vs. Combined Therapy
The type of HRT you take influences both risk and duration. If you’ve had a hysterectomy, you can take estrogen alone. If you still have your uterus, you need a progestogen alongside estrogen to prevent thickening of the uterine lining, which can raise the risk of endometrial cancer.
The risks of these two approaches are not identical. Combined therapy (estrogen plus progestogen) carries a somewhat higher breast cancer risk than estrogen alone. This difference can factor into how long your doctor feels comfortable keeping you on treatment and may shift the yearly risk-benefit calculation in one direction or the other.
Vaginal Estrogen Follows Different Rules
Low-dose vaginal estrogen, used for dryness, discomfort during sex, or urinary symptoms, is a different category from the systemic HRT that circulates through your whole body. Because vaginal estrogen is absorbed locally and reaches the bloodstream in only tiny amounts, it carries far fewer risks. Research from Harvard Health Publishing indicates it’s safe for at least a year of twice-weekly use without significant effects on uterine tissue. After a year, your doctor may want to evaluate the uterine lining, but many women use vaginal estrogen for years or even indefinitely. It’s not subject to the same risk-benefit pressures as systemic therapy.
What Happens When You Stop
One of the biggest reasons women hesitate to stop HRT is the return of symptoms, and the data suggests that concern is well-founded. In a Swedish population-based study, 87% of women who had hot flashes before starting HRT experienced them again after stopping. A separate clinical trial found that 60% of women developed hot flashes after being switched to a placebo, with symptoms peaking about eight weeks after cessation. Roughly one in four women who try to quit end up restarting within six months because symptoms are too disruptive.
The good news is that for most women, returning symptoms are temporary. They can last weeks to months, but they do tend to fade. The intensity is often less severe than what you experienced during the initial menopause transition.
Bone Loss Accelerates After Stopping
If you’ve been taking HRT partly for bone protection, stopping has measurable consequences. A French study (the OFELY study) found that women who discontinued HRT after six years of use lost bone at an annual rate of 0.7% to 1.6%, depending on the skeletal site measured. That rate was two to three times faster than the bone loss seen in women of the same age who had never taken HRT. In fact, the pace of loss after stopping closely resembled the rapid bone decline that happens in the first few years after menopause. If osteoporosis risk is a significant concern for you, this is an important factor in the decision to continue or to transition to a bone-specific treatment before stopping HRT.
Tapering Off vs. Stopping Abruptly
Many doctors suggest gradually reducing your dose rather than stopping cold turkey, though the evidence for one approach over the other is surprisingly thin. No large clinical trials have definitively proven that tapering reduces the severity or likelihood of returning symptoms compared to abrupt cessation. That said, tapering feels more comfortable for many women and gives you a chance to gauge how your body responds at lower doses before fully discontinuing. Common approaches include reducing the dose by half for a few months, switching to every-other-day dosing, or stepping down in stages over three to six months.
Regardless of the method, symptoms that do return typically show up within the first week or two after stopping and peak around the two-month mark.
The Annual Review
The British Menopause Society recommends that HRT dosage, type, and duration be evaluated at least once a year. This yearly review is your opportunity to reassess whether the benefits still outweigh the risks for your situation. The factors that matter most include how severe your symptoms still are, whether non-hormonal alternatives might now be effective for you, your current bone density, your cardiovascular health, and any changes in your breast cancer risk profile.
There is no age at which you are automatically “too old” for HRT. Healthy women at low cardiovascular and breast cancer risk can continue treatment into their 60s and beyond if symptoms persist and other therapies haven’t worked. The decision is yours and your doctor’s to make together, revisited as your health evolves over time.